Back to top
more

TG Therapeutics (TGTX)

(Delayed Data from NSDQ)

$13.91 USD

13.91
3,859,911

-0.07 (-0.50%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $13.91 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TGTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

TG Therapeutics, Inc. [TGTX]

Reports for Purchase

Showing records 41 - 60 ( 275 total )

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 41

12/01/2021

Company Report

Pages: 8

ODAC Meeting Planned for Ukoniq in Combination With Umbralisib as a Treatment for CLL and SLL; Lowering PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 42

11/05/2021

Company Report

Pages: 6

3Q21 Results; Approvals in RMS and CLL Expected in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 43

10/15/2021

Company Report

Pages: 8

Additional Results of the ULTIMATE I and II Trials Presented at ECTRIMS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 44

09/30/2021

Daily Note

Pages: 3

TG Therapeutics Announces BLA Submission for Ublituximab in Relapsing Forms of Multiple Sclerosis

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 45

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for TGTX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 46

09/20/2021

Company Report

Pages: 6

Positive U2 and Venetoclax Combination Data in CLL Highlights Several Presentations at the iwCLL Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 47

08/02/2021

Company Report

Pages: 6

2Q21 Results; Lowering Price Target Due to Decreased Revenue Expectations; Still Positive on the Future

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 48

06/07/2021

Company Report

Pages: 8

Solid Data for Monotherapy TG-1701 and in Combination With U2 at ASCO 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 49

05/25/2021

Company Report

Pages: 7

FDA Accepts BLA for Ukoniq in Combination With Ublituximab for CLL and SLL; PDUFA March 25, 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 50

05/13/2021

Daily Note

Pages: 3

Updated TG-1701 Data to be Presented at EHA and ASCO Meetings

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 51

05/10/2021

Company Report

Pages: 6

1Q21 Results; First Commercial Sales Reported; FDA Submission for CLL Complete, MS Submission Expected in 3Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 52

04/21/2021

Daily Note

Pages: 3

ULTRA-V Phase 3 Trial Enrollment Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 53

04/19/2021

Company Report

Pages: 8

Remarkable Phase 3 Ublituximab Data at AAN; BLA Submission Expected 3Q21; Raise PT by $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 54

03/29/2021

Daily Note

Pages: 3

Rolling BLA Submission for U2 in CLL Completed

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 55

03/02/2021

Company Report

Pages: 8

4Q20 Results; Ukoniq Launch Underway; Additional NDA Submissions and Potential Launches Coming in 2021 and 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 56

02/08/2021

Company Report

Pages: 8

Umbralisib, Now Ukoniq, Approved in MZL and FL Patients; Raising PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 57

01/19/2021

Company Report

Pages: 8

Many Catalysts Expected in 2021, Including First Commercial Launches; Raising PT to $78

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 58

12/10/2020

Company Report

Pages: 8

Positive Top-Line Results for Ubilituximab in Phase 3 Ultimate I and II Trials in MS; Raising PT to $61

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 59

12/08/2020

Company Report

Pages: 8

U2 and Venclexta Combination Data Impress at ASH 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 60

12/01/2020

Daily Note

Pages: 3

On a Roll; Rolling BLA For U2 in CLL Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party